Castle Biosciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
Castle Biosciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||
| current assets | |||||||||||||||||||||||||
| cash and cash equivalents | 82,233,000 | 89,689,000 | 119,709,000 | 94,959,000 | 85,572,000 | 82,949,000 | 98,841,000 | 91,223,000 | 95,874,000 | 114,821,000 | 122,948,000 | 134,180,000 | 273,166,000 | 309,017,000 | 329,633,000 | 363,177,000 | 368,339,000 | 406,981,000 | 409,852,000 | 183,050,000 | 179,759,000 | 98,653,000 | 98,845,000 | 94,474,818 | 17,468,466 |
| marketable investment securities | 193,697,000 | 185,462,000 | 173,421,000 | 184,826,000 | 174,116,000 | 156,264,000 | 144,258,000 | 138,530,000 | 129,634,000 | 117,234,000 | 135,677,000 | 131,802,000 | |||||||||||||
| accounts receivable | 52,311,000 | 56,353,000 | 51,218,000 | 50,261,000 | 45,988,000 | 42,699,000 | 38,302,000 | 37,003,000 | 31,314,000 | 27,728,000 | 23,476,000 | 22,835,000 | 22,606,000 | 19,910,000 | 17,282,000 | 18,532,000 | 17,817,000 | 14,292,000 | 12,759,000 | 12,618,000 | 12,528,000 | 14,600,000 | 14,648,000 | 12,369,260 | 9,730,319 |
| inventory | 8,366,000 | 6,849,000 | 8,135,000 | 6,572,000 | 8,013,000 | 7,645,000 | 7,942,000 | 5,769,000 | 6,121,000 | 4,520,000 | 3,980,000 | 3,802,000 | 3,365,000 | 2,350,000 | 2,021,000 | 2,375,000 | 2,124,000 | 2,310,000 | 2,217,000 | 1,679,000 | 1,667,000 | 1,219,000 | 1,237,000 | 821,658 | 550,894 |
| prepaid expenses and other current assets | 12,061,000 | 11,035,000 | 7,671,000 | 8,154,000 | 6,716,000 | 6,221,000 | 6,292,000 | 7,097,000 | 6,111,000 | 6,797,000 | 6,207,000 | 6,795,000 | 5,775,000 | 5,164,000 | 4,807,000 | 5,500,000 | 3,419,000 | 3,087,000 | 4,766,000 | 3,718,000 | 1,717,000 | 2,080,000 | 1,951,000 | 2,197,235 | 774,885 |
| total current assets | 348,668,000 | 349,388,000 | 360,154,000 | 344,772,000 | 320,405,000 | 295,778,000 | 295,635,000 | 279,622,000 | 269,054,000 | 271,100,000 | 292,288,000 | 299,414,000 | 304,912,000 | 336,441,000 | 353,743,000 | 389,584,000 | 391,699,000 | 426,670,000 | 429,594,000 | 201,065,000 | 195,671,000 | 116,552,000 | 116,681,000 | 109,862,971 | 28,524,564 |
| long-term accounts receivable | 1,132,000 | 1,000,000 | 918,000 | 1,106,000 | 1,125,000 | 1,056,000 | 1,191,000 | 1,338,000 | 1,227,000 | 1,218,000 | 1,087,000 | 1,187,000 | 1,367,000 | 1,406,000 | 1,308,000 | 1,410,000 | 1,313,000 | 1,121,000 | 1,096,000 | 1,045,000 | 652,000 | 756,000 | 870,000 | 1,451,872 | 1,266,098 |
| property and equipment | 74,060,000 | 55,423,000 | 51,122,000 | 44,383,000 | 38,638,000 | 32,904,000 | 25,433,000 | 22,273,000 | 20,511,000 | 18,254,000 | 14,315,000 | 13,054,000 | 11,203,000 | 9,385,000 | 9,501,000 | 8,866,000 | 8,092,000 | 7,780,000 | 7,102,000 | 6,646,000 | 5,024,000 | 2,733,000 | 2,060,000 | 1,798,236 | 1,743,170 |
| operating lease assets | 15,503,000 | 11,164,000 | 11,584,000 | 11,904,000 | 11,621,000 | 11,961,000 | 12,306,000 | 11,613,000 | 11,539,000 | 11,401,000 | 12,181,000 | 12,604,000 | 7,004,000 | 7,219,000 | 7,383,000 | ||||||||||
| goodwill and other intangible assets | 104,125,000 | 77,904,000 | 106,229,000 | 110,569,000 | 112,840,000 | 115,088,000 | 117,335,000 | 119,607,000 | 121,879,000 | 124,126,000 | 126,348,000 | 130,357,000 | 132,671,000 | ||||||||||||
| other assets – long-term | 1,241,000 | 1,266,000 | 1,228,000 | 1,831,000 | 2,683,000 | 1,720,000 | 1,440,000 | 1,566,000 | 1,190,000 | 792,000 | 1,110,000 | 1,195,000 | 1,223,000 | 2,699,000 | 1,715,000 | 1,728,000 | 1,631,000 | 1,761,000 | 1,536,000 | 1,638,000 | 199,000 | 216,000 | 135,000 | 87,168 | 1,813,311 |
| total assets | 544,729,000 | 501,715,000 | 531,235,000 | 514,565,000 | 487,312,000 | 458,507,000 | 453,340,000 | 436,019,000 | 425,400,000 | 426,891,000 | 447,329,000 | 457,811,000 | 458,380,000 | 444,425,000 | 462,572,000 | 433,692,000 | 435,533,000 | 437,332,000 | 439,328,000 | 210,394,000 | 201,546,000 | 120,257,000 | 119,746,000 | 113,200,247 | 33,347,143 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||||
| current liabilities | |||||||||||||||||||||||||
| accounts payable | 13,181,000 | 8,502,000 | 6,901,000 | 6,810,000 | 9,540,000 | 9,318,000 | 10,268,000 | 6,929,000 | 7,135,000 | 9,961,000 | 4,731,000 | 5,768,000 | 3,281,000 | 3,314,000 | 2,546,000 | 2,766,000 | 1,368,000 | 2,172,000 | 2,098,000 | 2,101,000 | 2,495,000 | 1,934,000 | 1,865,000 | 1,251,267 | 2,084,910 |
| accrued compensation | 24,973,000 | 17,857,000 | 32,555,000 | 27,672,000 | 21,239,000 | 14,708,000 | 28,945,000 | 22,405,000 | 17,298,000 | 12,796,000 | 24,358,000 | 19,532,000 | 14,850,000 | 8,566,000 | 15,483,000 | 12,120,000 | 8,584,000 | 5,208,000 | 9,108,000 | 6,354,000 | 4,651,000 | 3,134,000 | 5,779,000 | 3,676,164 | 2,784,746 |
| contingent consideration | 1,000,000 | 20,849,000 | 18,287,000 | ||||||||||||||||||||||
| operating lease liabilities | 1,571,000 | 1,435,000 | 1,665,000 | 1,745,000 | 1,226,000 | 1,189,000 | 1,137,000 | 1,091,000 | 1,966,000 | 1,779,000 | 1,777,000 | 1,535,000 | 1,211,000 | 1,199,000 | 1,179,000 | ||||||||||
| current portion of long-term debt | 1,944,000 | 1,111,000 | 278,000 | 10,000,000 | 10,000,000 | 8,333,000 | 5,833,000 | 3,333,333 | 833,333 | ||||||||||||||||
| other accrued and current liabilities | 8,221,000 | 8,369,000 | 7,993,000 | 8,068,000 | 7,449,000 | 6,744,000 | 7,317,000 | 5,899,000 | 7,318,000 | 5,607,000 | 5,262,000 | 5,107,000 | 8,177,000 | 5,593,000 | 5,678,000 | ||||||||||
| total current liabilities | 50,890,000 | 37,274,000 | 49,392,000 | 44,295,000 | 39,454,000 | 31,959,000 | 47,667,000 | 36,324,000 | 33,717,000 | 30,143,000 | 36,128,000 | 31,942,000 | 27,519,000 | 39,521,000 | 24,886,000 | 20,993,000 | 18,654,000 | 17,578,000 | 20,876,000 | 30,240,000 | 28,242,000 | 15,256,000 | 15,289,000 | 9,237,741 | 11,745,674 |
| long-term debt | 8,096,000 | 8,921,000 | 9,745,000 | 10,015,000 | 10,008,000 | 10,000,000 | 12,455,000 | 14,741,000 | 17,013,000 | 19,289,000 | 21,570,372 | 23,858,781 | |||||||||||||
| noncurrent portion of contingent consideration | 1,500,000 | 1,798,000 | 1,949,000 | ||||||||||||||||||||||
| noncurrent operating lease liabilities | 25,377,000 | 14,049,000 | 14,345,000 | 14,691,000 | 13,645,000 | 13,864,000 | 14,173,000 | 13,435,000 | 12,427,000 | 11,103,000 | 11,533,000 | 11,900,000 | 6,480,000 | 6,711,000 | 6,900,000 | ||||||||||
| noncurrent finance lease liabilities | 364,000 | 328,000 | 311,000 | 289,000 | 312,000 | ||||||||||||||||||||
| deferred tax liability | 3,126,000 | 837,000 | 1,607,000 | 4,220,000 | 206,000 | 206,000 | 441,000 | 441,000 | 441,000 | 428,000 | 614,000 | 614,000 | 757,000 | 635,000 | |||||||||||
| total liabilities | 89,353,000 | 61,409,000 | 75,400,000 | 73,510,000 | 63,419,000 | 56,045,000 | 62,071,000 | 50,236,000 | 46,632,000 | 41,742,000 | 48,179,000 | 46,378,000 | 36,720,000 | 47,089,000 | 50,832,000 | 21,979,000 | 19,617,000 | 18,745,000 | 23,637,000 | 43,835,000 | 43,924,000 | 32,323,000 | 34,633,000 | 30,864,119 | 36,940,985 |
| commitments and contingencies | |||||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of june 30, 2025 and december 31, 2024; no shares issued and outstanding as of june 30, 2025 and december 31, 2024 | |||||||||||||||||||||||||
| common stock | 29,000 | 29,000 | 28,000 | 28,000 | 28,000 | 28,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 26,000 | 26,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 20,000 | 19,000 | 17,000 | 17,000 | 17,074 | 2,192 |
| additional paid-in capital | 676,759,000 | 666,120,000 | 655,703,000 | 650,270,000 | 636,022,000 | 623,450,000 | 609,477,000 | 601,618,000 | 587,771,000 | 575,367,000 | 560,409,000 | 551,883,000 | 541,672,000 | 515,701,000 | 505,482,000 | 499,046,000 | 491,458,000 | 485,338,000 | 478,162,000 | 224,146,000 | 210,621,000 | 139,559,000 | 137,308,000 | 136,585,399 | 9,910,882 |
| accumulated deficit | -221,451,000 | -225,974,000 | -200,126,000 | -209,716,000 | -211,985,000 | -220,905,000 | -218,371,000 | -215,791,000 | -208,886,000 | -190,109,000 | -160,905,000 | -140,287,000 | -120,038,000 | -118,390,000 | -93,767,000 | -87,358,000 | -75,567,000 | -66,776,000 | -62,496,000 | -57,607,000 | -53,018,000 | -51,642,000 | -52,212,000 | -54,266,345 | -60,115,640 |
| accumulated other comprehensive income | 39,000 | 131,000 | 230,000 | 473,000 | -172,000 | -111,000 | 136,000 | ||||||||||||||||||
| total stockholders’ equity | 455,376,000 | 440,306,000 | 455,835,000 | 441,055,000 | 423,893,000 | 402,462,000 | 391,269,000 | 385,783,000 | 378,768,000 | 385,149,000 | 399,150,000 | 411,433,000 | 421,660,000 | 397,336,000 | 411,740,000 | 411,713,000 | 415,916,000 | 418,587,000 | 415,691,000 | 166,559,000 | 157,622,000 | 87,934,000 | 85,113,000 | 82,336,128 | |
| total liabilities and stockholders’ equity | 544,729,000 | 501,715,000 | 531,235,000 | 514,565,000 | 487,312,000 | 458,507,000 | 453,340,000 | 436,019,000 | 425,400,000 | 426,891,000 | 447,329,000 | 457,811,000 | 458,380,000 | 444,425,000 | 462,572,000 | 433,692,000 | 435,533,000 | 437,332,000 | 439,328,000 | 210,394,000 | 201,546,000 | 120,257,000 | |||
| long-term marketable investment securities | 5,570,000 | ||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of march 31, 2025 and december 31, 2024; no shares issued and outstanding as of march 31, 2025 and december 31, 2024 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of december 31, 2024 and 2023; no shares issued and outstanding as of december 31, 2024 and 2023. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of september 30, 2024 and december 31, 2023; no shares issued and outstanding as of september 30, 2024 and december 31, 2023 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of june 30, 2024 and december 31, 2023; no shares issued and outstanding as of june 30, 2024 and december 31, 2023 | |||||||||||||||||||||||||
| other liabilities | 16,000 | 25,000 | 36,000 | 47,000 | 55,000 | 90,000 | 124,000 | 158,000 | 100,000 | 124,000 | |||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of march 31, 2024 and december 31, 2023; no shares issued and outstanding as of march 31, 2024 and december 31, 2023 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of december 31, 2023 and 2022; no shares issued and outstanding as of december 31, 2023 and 2022. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of september 30, 2023 and december 31, 2022; no shares issued and outstanding as of september 30, 2023 and december 31, 2022 | |||||||||||||||||||||||||
| accumulated other comprehensive loss | -71,000 | -144,000 | -136,000 | -381,000 | -189,000 | ||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of june 30, 2023 and december 31, 2022; no shares issued and outstanding as of june 30, 2023 and december 31, 2022 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of march 31, 2023 and december 31, 2022; no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of december 31, 2022 and 2021; no shares issued and outstanding as of december 31, 2022 and 2021. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of september 30, 2022 and december 31, 2021; no shares issued and outstanding as of september 30, 2022 and december 31, 2021 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of june 30, 2022 and december 31, 2021; no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | |||||||||||||||||||||||||
| intangible assets | 87,275,000 | 88,922,000 | |||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized as of march 31, 2022 and december 31, 2021; no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | |||||||||||||||||||||||||
| medicare advance payment | 2,999,000 | 6,177,000 | 8,178,000 | 6,615,000 | 8,350,000 | 8,350,000 | |||||||||||||||||||
| noncurrent portion of medicare advance payment | 172,000 | 1,735,000 | |||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of december 31, 2021 and 2020; no shares issued and outstanding as of december 31, 2021 and 2020. | |||||||||||||||||||||||||
| intangible asset | 32,104,000 | 32,798,000 | |||||||||||||||||||||||
| other accrued liabilities | 3,108,000 | 2,525,000 | 2,020,000 | 3,055,000 | 3,435,000 | 2,746,000 | 1,855,000 | 1,812,000 | 976,977 | 1,616,866 | |||||||||||||||
| deferred rent and other liabilities | 986,000 | 963,000 | 995,000 | 1,026,000 | 1,140,000 | 941,000 | |||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of september 30, 2021 and december 31, 2020; no shares issued and outstanding as of september 30, 2021 and december 31, 2020. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of june 30, 2021 and december 31, 2020; no shares issued and outstanding as of june 30, 2021 and december 31, 2020. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of march 31, 2021 and december 31, 2020; no shares issued and outstanding as of march 31, 2021 and december 31, 2020. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of december 31, 2020 and 2019; no shares issued and outstanding as of december 31, 2020 and 2019. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of september 30, 2020 and december 31, 2019; no shares issued and outstanding as of september 30, 2020 and december 31, 2019. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of june 30, 2020 and december 31, 2019; no shares issued and outstanding as of june 30, 2020 and december 31, 2019. | |||||||||||||||||||||||||
| deferred rent liability | 54,000 | 55,000 | 56,006 | 56,690 | |||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized as of march 31, 2020 and december 31, 2019; no shares issued and outstanding as of march 31, 2020 and december 31, 2019. | |||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||||
| preferred stock warrant liability | 1,279,840 | ||||||||||||||||||||||||
| convertible preferred stock | |||||||||||||||||||||||||
| convertible preferred stock series c, 0.001 par value, zero and 503,056 shares authorized as of december 31, 2019 and 2018, respectively; zero and 503,056 shares issued and outstanding as of december 31, 2019 and 2018, respectively; 0 and 2,417 aggregate liquidation preference as of december 31, 2019 and 2018, respectively. | |||||||||||||||||||||||||
| redeemable convertible preferred stock | 45,107,730 | ||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 and zero shares authorized as of december 31, 2019 and 2018, respectively; no shares issued and outstanding as of december 31, 2019 and 2018. | |||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 119,746,000 | 113,200,247 | |||||||||||||||||||||||
| convertible preferred stock series c, 0.001 par value, zero and 503,056 shares authorized as of september 30, 2019 and december 31, 2018, respectively; zero and 503,056 shares issued and outstanding as of september 30, 2019 and december 31, 2018, respectively; 0 and 2,417,195 aggregate liquidation preference as of september 30, 2019 and december 31, 2018, respectively. | |||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 and zero shares authorized as of september 30, 2019 and december 31, 2018, respectively; no shares issued and outstanding as of september 30, 2019 and december 31, 2018. | |||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ deficit | |||||||||||||||||||||||||
| convertible promissory notes | 4,425,819 | ||||||||||||||||||||||||
| convertible preferred stock series c, 0.001 par value, 503,056 shares authorized as of june 30, 2019 and december 31, 2018; 503,056 shares issued and outstanding as of june 30, 2019 and december 31, 2018; 2,486,645 and 2,417,195 aggregate liquidation preference as of june 30, 2019 and december 31, 2018, respectively. | 1,500,994 | ||||||||||||||||||||||||
| stockholders’ deficit | |||||||||||||||||||||||||
| total stockholders’ deficit | -50,202,566 | ||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ deficit | 33,347,143 | ||||||||||||||||||||||||
| castle biosciences, inc.condensed statements of operations and comprehensive loss | |||||||||||||||||||||||||
| net revenues | 10,738,569 | ||||||||||||||||||||||||
| cost of sales | 1,992,784 | ||||||||||||||||||||||||
| gross margin | 8,745,785 | ||||||||||||||||||||||||
| operating expenses | |||||||||||||||||||||||||
| research and development | 1,317,237 | ||||||||||||||||||||||||
| selling, general and administrative | 6,820,927 | ||||||||||||||||||||||||
| total operating expenses | 8,138,164 | ||||||||||||||||||||||||
| operating income | 607,621 | ||||||||||||||||||||||||
| interest income | 5,529 | ||||||||||||||||||||||||
| interest expense | -1,692,582 | ||||||||||||||||||||||||
| other income | -189,647 | ||||||||||||||||||||||||
| income before income taxes | -1,269,079 | ||||||||||||||||||||||||
| income tax expense | |||||||||||||||||||||||||
| net income and comprehensive loss | -1,269,079 | ||||||||||||||||||||||||
| convertible preferred stock cumulative dividends | 938,892 | ||||||||||||||||||||||||
| accretion of redeemable convertible preferred stock to redemption value | 56,775 | ||||||||||||||||||||||||
| net income and comprehensive loss attributable to common stockholders | -2,264,746 | ||||||||||||||||||||||||
| loss per share attributable to common stockholders, basic and diluted | -1.05 | ||||||||||||||||||||||||
| weighted-average shares outstanding, basic and diluted | 2,152,965 |
We provide you with 20 years of balance sheets for Castle Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Castle Biosciences. Explore the full financial landscape of Castle Biosciences stock with our expertly curated balance sheets.
The information provided in this report about Castle Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.